Artiva Biotherapeutics (ARTV) Receivables - Net (2023 - 2024)

Artiva Biotherapeutics (ARTV) reported Receivables - Net of $569000.0 for Q3 2024, little changed quarter-over-quarter from $569000.0 in Q2 2024.

Artiva Biotherapeutics (ARTV) Receivables - Net (2023 - 2024) Analysis & Trends

Artiva Biotherapeutics (ARTV) has 2 years of Receivables - Net data on file, last reported at $569000.0 in Q3 2024.

Receivables - Net for Q3 2024 came in at $569000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2024 was $569000.0 (changed N/A YoY), and the FY2023 annual result was $1.0 million, changed N/A from the prior year.
Receivables - Net steadied at $569000.0 in Q3 2024 per ARTV's latest filing, from $569000.0 in the prior quarter.
Over five years, Receivables - Net peaked at $1.0 million in Q4 2023 and troughed at $569000.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Artiva Biotherapeutics	241.85 Mn	241.85 Mn	-

Download Data